Inve India ▾

Jeena Sikho share price & results

Jeena Sikho· Consumer Services· Consumer Discretionary

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Pan-India Ayurveda hospital/clinic operator ('Shuddhi') with a ~330-SKU Ayurvedic products business.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue224 ₹ crore+28.7% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin41.0 %−4.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit66.0 ₹ crore+29.4% YoYQuarterly, as filedQuarter to Jun 2026Profit after tax as filed.
Return on equity65.56 %+31.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM to Jun 2026Adjusted profit attributable to owners ÷ average owners’ equity.
Free cash flow margin27.59 %+18.0 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)56.91 %+31.3 ptsFY Mar 2026 vs FY Mar 2023Trailing twelve monthsTTM to Jun 2026Revenue change against the same period one year earlier.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

5 of 8 judged targets kept · 14 open · verdicts reflect calls analysed to Q1 FY27.

Jeena Sikho management guidance track record on Inve: 22 targets tracked across analysed earnings calls (5 achieved, 3 missed, 14 open).

TargetOriginal wordingSaidLatest callVerdict
FY25 RevenueINR450 crores
Call transcript, Q2 FY25 · 13 Nov 2024		Q2 FY25Q1 FY27:No new information. Promise concluded.
Call transcript, Q1 FY27 · 10 Aug 2026		Achieved
FY25 PAT Margin25%
Call transcript, Q2 FY25 · 13 Nov 2024		Q2 FY25Q1 FY27:No new information. Promise concluded.
Call transcript, Q1 FY27 · 10 Aug 2026		Missed
Occupancy Rate70-80%
Call transcript, Q4 FY25 · 20 May 2025		Q4 FY25Q1 FY27:Occupancy for the quarter was 59%. Management reiterated the target: 'And I have to take the occupancy to 75%,80%.'
Call transcript, Q1 FY27 · 10 Aug 2026		At Risk

Source: Inve Guidance Tracker for Jeena Sikho · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

3 of Jeena Sikho's 22 targets were missed. See which ones, and which are quietly gone. The 3 above are the free sample; 19 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹344.5 −0.06% · −₹0.2

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance −53.0% 1Y

₹400₹500₹600₹700₹800Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26Q2 FY26 — 7 Nov 2025Q3 FY26 — 9 Feb 2026Q4 FY26 — 2 Jun 2026Q1 FY27 — 10 Aug 2026

1Y: ₹733.05 on 24 Oct 2025 → ₹344.5. High ₹794 (7 Nov 2025), low ₹341.55 (23 Oct 2026).

Previous close
₹344.7
Market cap
₹4.3k Cr
52-week range
₹341.55 – ₹794
One year
−53.54%
Price to earnings (TTM to Jun 2026)
18.08×
Return on equity (TTM to Jun 2026)
65.56%

Overview

Symbol
NSE:JSLL
Industry
Consumer Discretionary
Exchange
NSE
Currency
INR

What Jeena Sikho does

Based on the company's own presentations, annual report and earnings calls.

Jeena Sikho Lifecare runs a dual-vertical Ayurveda healthcare business: a nationwide network of hospitals, clinics and day-care centres delivering in-patient, out-patient, Panchakarma and home-based therapy services, alongside a separate Ayurvedic products business selling ~330 SKUs of herbal formulations under the 'Shuddhi' brand. Facilities operate on a hub-and-spoke model, pairing large owned Ayurveda hospitals with smaller company-run and franchisee-operated clinics and day-care centres; at franchisee sites, Ayurveda doctors remain on JSLL's payroll and medicines are supplied exclusively by JSLL. Products are sold through the company's own healthcare centres, tele-calling and e-commerce channels, and to franchisees, with manufacturing outsourced to a network of third-party manufacturers. The company is empanelled with several state government health schemes, CGHS/CAPF/ECHS, central armed police forces and private insurers for patient billing.

Segments

  • Ayurveda Healthcare Services
  • Ayurveda Healthcare Products
Operational hospitals
61
Operational clinics & day-care centres
58
Total bed capacity (operational + pipeline)
2,861 beds (2,300 operational, 445 in pipeline)
States covered
23
Cities & towns covered
100+
SKUs in Ayurveda medicine & product portfolio
330+
Founded 2009Headquarters Zirakpur, Punjab, India Company website

How the price took the results

close before → close after

Q1 FY27
−9.7%
10 Aug
Q4 FY26
+20.0%
2 Jun
Q3 FY26
+4.0%
9 Feb
Q2 FY26
+1.1%
7 Nov

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for Jeena Sikho

Free account: one company. Everything above stays public.

Write why you follow Jeena Sikho and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Consumer Services companies

All Consumer Services companies → · Consumer Services earnings growth →

Learn to analyse Jeena Sikho

Guides on how to read this kind of business and the numbers that matter.